These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 200161)

  • 1. Type III hyperlipoproteinemia: paradoxical hypolipidemic response to estrogen.
    Kushwaha RS; Hazzard WR; Gagne C; Chait A; Albers JJ
    Ann Intern Med; 1977 Nov; 87(5):517-25. PubMed ID: 200161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The spectrum of electrophoretic mobility of very low density lipoproteins: role of slower migrating species in endogenous hypertriglyceridemia (type IV hyperlipoproteinemia) and broad-beta disease (type III).
    Hazzard ER; Bierman EL
    J Lab Clin Med; 1975 Aug; 86(2):239-52. PubMed ID: 168277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of the hypolipidemic effect of estrogen in type III hyperlipoproteinemia.
    Stuyt PM; Demacker PN; van't Laar A
    Horm Metab Res; 1986 Sep; 18(9):607-10. PubMed ID: 3465673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed clearance of chylomicron remnants following vitamin-A-containing oral fat loads in broad-beta disease (type III hyperlipoproteinemia).
    Hazzard WR; Bierman EL
    Metabolism; 1976 Jul; 25(7):777-801. PubMed ID: 181657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of estrogen therapy on apolipoprotein E in type II hyperlipoproteinemia.
    Falko JM; Schonfeld G; Witztum JL; Kolar J; Weidman SW
    Metabolism; 1979 Nov; 28(11):1171-7. PubMed ID: 226834
    [No Abstract]   [Full Text] [Related]  

  • 6. Impaired very low density lipoprotein and triglyceride removal in broad beta disease: comparison with endogenous hypertriglyceridemia.
    Chait A; Hazzard WR; Albers JJ; Kushwaha RP; Brunzell JD
    Metabolism; 1978 Sep; 27(9):1055-66. PubMed ID: 210351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by very low density lipoproteins of subjects with hypertriglyceridemia.
    Gianturco SH; Gotto AM; Jackson RL; Patsch JR; Sybers HD; Taunton OD; Yeshurun DL; Smith LC
    J Clin Invest; 1978 Feb; 61(2):320-8. PubMed ID: 202612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type III hyperlipoproteinemia: an analysis of two contemporary definitions.
    Fredrickson DS; Morganroth J; Levy RI
    Ann Intern Med; 1975 Feb; 82(2):150-7. PubMed ID: 163607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inheritance of type-III hyperlipoproteinemia. Lipoprotein patterns in first-degree relatives.
    Vessby B; Hedstrand H; Lundin LG; Olsson U
    Metabolism; 1977 Mar; 26(3):225-54. PubMed ID: 189159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
    Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
    J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type III hyperlipoproteinemia: diagnosis in whole plasma by apolipoprotein-E immunoassay.
    Kushwaha RS; Hazzard WR; Wahl PW; Hoover JJ
    Ann Intern Med; 1977 Nov; 87(5):509-16. PubMed ID: 200160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertriglyceridaemia associated with an abnormal triglyceride-rich lipoprotein carrying excess apolipoprotein C-III-2.
    Stocks J; Holdsworth G; Galton D
    Lancet; 1979 Sep; 2(8144):667-71. PubMed ID: 90760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lipid composition of circulating lipoproteins in various types of hyperlipoproteinemia (author's transl)].
    Jaillard J; Sezille G; Dewailly P; Fruchart JC
    Diabete Metab; 1977 Sep; 3(3):159-64. PubMed ID: 199484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catabolism of very-low-density lipoproteins in subjects with broad beta disease: comparison with endogenous hypertriglyceridemia.
    Kushwaha RS; Chait A; Hazzard WR
    J Lab Clin Med; 1982 Jan; 99(1):15-24. PubMed ID: 6948063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins.
    Walsh BW; Schiff I; Rosner B; Greenberg L; Ravnikar V; Sacks FM
    N Engl J Med; 1991 Oct; 325(17):1196-204. PubMed ID: 1922206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hypolipidemic effect of cholestyramine in patients affected by type II hyperlipoproteinemia].
    Sauvanet JP; Drouin P; Mejean L; Lambert D; Debry G
    Therapie; 1978; 33(5):615-22. PubMed ID: 217121
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric familial type III hyperlipoproteinemia.
    Glueck CJ; Fallat RW; Mellies MJ; Steiner PM
    Metabolism; 1976 Nov; 25(11):1269-74. PubMed ID: 185489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss.
    Ginsberg HN; Le NA; Gibson JC
    J Clin Invest; 1985 Feb; 75(2):614-23. PubMed ID: 3973021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.